abrdn plc bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,126,987 shares of the company's stock, valued at approximately $12,656,000. abrdn plc owned approximately 0.14% of Roivant Sciences at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in Roivant Sciences in the fourth quarter valued at $33,000. Allspring Global Investments Holdings LLC bought a new stake in Roivant Sciences in the third quarter valued at $44,000. Covestor Ltd grew its position in Roivant Sciences by 165,040.0% in the third quarter. Covestor Ltd now owns 8,257 shares of the company's stock valued at $96,000 after acquiring an additional 8,252 shares during the period. Vontobel Holding Ltd. grew its position in Roivant Sciences by 16.7% in the third quarter. Vontobel Holding Ltd. now owns 15,782 shares of the company's stock valued at $184,000 after acquiring an additional 2,258 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Roivant Sciences by 99.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,797 shares of the company's stock worth $231,000 after purchasing an additional 9,856 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.
Roivant Sciences Trading Up 1.4 %
NASDAQ:ROIV traded up $0.15 during mid-day trading on Friday, hitting $11.03. The company had a trading volume of 3,109,699 shares, compared to its average volume of 6,730,673. Roivant Sciences Ltd. has a fifty-two week low of $8.06 and a fifty-two week high of $13.24. The business's fifty day moving average is $10.92 and its two-hundred day moving average is $10.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. The firm has a market cap of $8.89 billion, a P/E ratio of 2.12 and a beta of 1.34.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. As a group, research analysts expect that Roivant Sciences Ltd. will post -1.36 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have recently commented on ROIV. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday. Deutsche Bank Aktiengesellschaft raised their price target on Roivant Sciences from $14.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. Piper Sandler assumed coverage on Roivant Sciences in a report on Friday, January 5th. They issued an "overweight" rating and a $20.00 price target on the stock. TheStreet upgraded Roivant Sciences from a "d" rating to a "c+" rating in a report on Tuesday, February 13th. Finally, Truist Financial reiterated a "buy" rating and issued a $23.00 price target on shares of Roivant Sciences in a report on Monday, March 25th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of "Moderate Buy" and a consensus target price of $16.90.
Check Out Our Latest Stock Analysis on Roivant Sciences
Insider Activity at Roivant Sciences
In related news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares of the company's stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.60% of the stock is owned by insiders.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
